2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms, Plasma Cell
1
Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Influenza, Human
1
Interventions
Influenza Vaccines
16
trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine
2
Vaccines
2
Oseltamivir
2
FluMist
2
Cyclophosphamide
2
ziprasidone
1
vaxigrip
1
thymoglobulin
1
peginterferon alfa-2a
1
influvac
1
fludarabine
1
baloxavir
1
Zolpidem
1
Warfarin
1
Vecuronium Bromide
1
Vancomycin
1
Tranexamic Acid
1
Tobramycin
1
Starch
1
Spironolactone
1
Sevelamer
1
SARS-CoV-2 inactivated vaccines
1
Rocuronium
1
Rituximab
1
Piperacillin, Tazobactam Drug Combination
1
Pentobarbital
1
Oxycodone
1
Nivolumab
1
Nifedipine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Influenza, Human
×
Fluzone High-Dose
×
Clear all
NCT01666782
2016-06-24
IMMUNE
Rochester General Hospital
Phase 2
Completed
105 enrolled
10 charts